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the medicine for the rare indication as distinct from the costs of the medicine for
the common disease.
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OBJECTIVES: The present study contributes to and augments the few economic
attempts to explain medical non-compliance. To this end, an “economic invest-
ment model” is suggested as conceptual framework reflecting the three phases
typically observed in medical treatments: “invasion”, “high compliance” and ex-
pected variations in compliance behavior. Based on this framework a cost-neutral
incentive scheme is developed; the impact of this incentive scheme on adherence
is evaluated.METHODS: Behavioral predictionswere empirically evaluated by sug-
gesting an experimental design that incorporates the key features of the concep-
tual framework. Computerized economic experiments with investment decisions
over 12 periodswere run (September - December 2011)with subjects recruited from
a pool of approx. 1800 students from different fields of study. 107 and 102 subjects
participated in the baseline and in the incentive treatment, respectively. Instruc-
tionswere context-free, thus no associationswithmedical treatments, pharmacies
etc. could emerge, possibly influencing subjects’ decisions in an uncontrolled way.
RESULTS: In the baseline treatment, adherence drops significantly closely before
(p0.03, McNemar, two-sided) and closely after (p0.016, McNemar, two-sided) a
reference point (period 6), which is constituted by costs imposed by the invasion
phase. In the incentive treatment only one significant drop from period 9 to 10
(p.016, McNemar, two-sided) exists. Especially in the last periods of the experi-
ment the proportion of subjects switching to non-adhere is weakly significantly
higher in the baseline treatment than in the treatment with monetary incentives
(p0.06, Wilcoxon, two-sided). CONCLUSIONS: Decisions predicted by behavioral
economic theories similar to those documented in other contexts are at play in this
experimental setup and explain why adherence switches to non-adherence at
some point. By using financial incentives this switching point is shifted towards
the end of the “therapeutic treatment”. Thus, adherence is observed over a longer
span compared to a design providing no financial incentives.
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OBJECTIVES: Large amounts of health care cost are spent on drugs in Korea, 29.6%
of total health care expenditure in 2009, and these amounts are continuously in-
creasing. To control spending on prescription drugs we had tried to adopt the
reference pricing system in 2001, but it failed due to patients’ negative perception
and shortage of infrastructure. Recently, it is estimated that the technical circum-
stances are prepared. Yet the public perception has not been checked whether it
has been changed or not. The aim of this study was to ascertain the patients’
willingness to exchange the prescribed drug for the cheaper one in order to predict
the acceptability of the reference price system.METHODS: Nation-wide telephone
interview survey was conducted for 1000 consumers from October 19 to 26, 2011.
RESULTS: Patients were asked whether they would exchange the drug prescribed
by their doctor for the cheaper drug of which therapeutic effectiveness is equiva-
lent. Of 1000 respondents, 647(64.7%) answered “Yes (I will exchange)”. And the
reasons of the 353 consumers who responded “No (I will not exchange)” are; their
trust in doctor’s judgment (56.1%, n198), little confidence in the equivalence be-
tween the medications (35.1%, n124), and there is no great difference among the
cost ofmedicines in general (8.8%, n31).CONCLUSIONS: Patients’ attitude toward
lower price drug has been changed for last 10 years in Korea. They would likely to
choose cheaper drugs if information of exchangeable drug options and prices is
given at the time of prescribing or dispensing. It means that reference price system
would be acceptable by patients and contribute to reduce the pharmaceutical ex-
penditure in Korea. In addition, providing physicians with incentives to encourage
prescribing low pricemedicines and restoring consumer confidence in equivalence
of therapeutic effect are required to improve the effectiveness of the system.
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OBJECTIVES: Potential savings from generic drugs has become a key issue among
Canadian policy makers, with public drug programs in many Canadian provinces
reducing the amount they are willing to pay for generic drugs. This analysis exam-
ines generic drug spending in Canada, and looks at future patent expiries to esti-
mate the potential for savings in coming years. METHODS: This study examined
wholesale purchase data from IMS Brogan’s Canadian Drug Store and Hospital
Purchases Audit for all Canadian provinces between October 2004 and September
2010. Health Canada’s Patent Register and Drug Product Database were used to
estimate future dates of generic entry. RESULTS: Between 2004-05 and 2009-10,
purchases of generic drugs grew at 15.0% per year, three times faster than pur-
chases of brand name drugs. This increased the generic share of the Canadian drug
market from 17.0% to 25.9%. Further increases in the generic share are expected as
drugs with patents expiring between 2010 and 2014 accounted for 38.2% of all
purchases of prescription drugs in Canada in 2009. Drugs with patents expiring
beyond 2014 accounted for only 8.2% of drug purchases. CONCLUSIONS: Findings
suggest that there is potential for significant savings arising from new generic
competition in the next few years. The magnitude of these savings will depend on
the degree to which policy changes impact generic prices. However, theremay less
opportunity in the longer term. This issue is compounded by uncertainty as to the
regulatory requirements, manufacturing processes and pricing for “generic” ver-
sions of biologics.
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OBJECTIVES: To report ustekinumab dosing patterns in a large United States (U.S.)
retrospective healthcare claims database. METHODS: Patients with ustekinumab
prescriptions between 9/25/2009 and 12/31/2010 (first claim set index date) and
continuous activity in the Source® LX database (6 months pre- and 6 months
post-index) were included. Patients with evidence of other biologics during usteki-
numab treatment were excluded. Dosing was evaluated for the first 5 prescription
fills. Dose changeswere assessed for subsequent doses post-index and classified as
“higher than”, “same as”, or “lower than” the initial dose. The dosing interval was
defined as days between consecutive fills. Biologic experience was defined as  1
claim for another biologic pre-index. RESULTS: A total of 473 patients were evalu-
ated (meanSD agewas 4912 years; 46.3% female). 64.7% (n306) of patientswere
bio-experienced, while 35.3% (n167) had no history of biologic use before usteki-
numab (bio-naïve). Initial doses of 45 mg were observed for 69.3% of bio-experi-
enced and 72.5% of bio-naïve patients. Initial doses of 90 mg were observed for
30.7% of bio-experienced and 27.5% of bio-naïve patients. Subsequent doses were
the same as or lower than the initial dose for the majority of all (92.2%-96.8%),
bio-experienced (91.6%-97.7%), and bio-naïve (90.2%-95.2%) patients at each fill.
Overall median/mean dosing interval was 28/34 days for the first to second fill.
Median/mean dosing intervals for subsequent fills spanned 86-88/85-89 days. Dos-
ing intervals were similar among bio-experienced and bio-naïve patients.
CONCLUSIONS: In this longitudinal study of ustekinumab utilization in a US
healthcare claims database, nearly three-quarters of ustekinumab users had prior
treatmentwith biologics. Over two-thirds of initial ustekinumab doseswere 45mg.
Most patients remained at or below their starting dose. Dosing intervals were con-
sistent with prescribing recommendations (approximately one month for first 2
doses, followed by quarterly intervals). Dosing patterns in bio-experienced and
bio-naïve patients were similar.
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OBJECTIVES: To identify factors associated with primary nonadherence [PNA].
METHODS: This retrospective cohort study identified all new prescriptionswritten in
an integrated health care system for 10 therapeutic drug groups over a three-month
period (12/1/2009 - 2/28/2010). Study drugs included: antiinfectives, analgesics, mi-
graine medications, antidiabetics, osteoporosis medications, cardiovascular agents,
antihyperlipidemics, antiasthmatics, antidepressants, and anticoagulants. PNA was
defined as the failure to fill a prescription within 14 days of when it was written.
Stepwise multivariable logistic regression was used to identify significant patient,
provider and prescription characteristics associated with PNA. RESULTS: A total of
569,095 new prescriptions were written for the study drugs of interest during the
study period. Across all drug groups, the PNA rate was 9.8%. PNA rates for individ-
ual drug groups varied and were highest for osteoporosis medications (22.4%) and
antihyperlipidemics (22.3%). Patients were more likely to be primary nonadherent
if they were black, were not prescribed any drug from the same therapeutic drug
group during the past year, or had certain baseline comorbidities. Also, patients
who received brand name or multiple concomitant prescriptions were more likely
to be primary nonadherent. In contrast, patientswhofilled at least one prescription
in the prior year, had dual insurance orMedicaid coverage, or had a prescription for
a symptomatic disease were more likely to fill their prescription. Patients who
received prescriptions written by emergency medicine, pediatrics, or urgent care
were less likely to be primary nonadherent. Factors associated with PNA were
mostly consistent across all drug groups, but the estimated direction and signifi-
cance of some factors, such as patient gender and age, depended on whether the
treatment was acute or chronic. CONCLUSIONS: These results may be used to
facilitate clinicians and payers in making informed decisions when designing and
implementing cost-effective patient interventions to improve overall adherence to
medications.
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OBJECTIVES: To compare rates of Complementary and AlternativeMedicine (CAM)
use among individuals with and without disabilities.METHODS:We used a cross-
sectional design. Our data source was the 2007 National Health Interview Survey
files and the Adult Complementary and AlternativeMedicine Supplement. Individ-
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